Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 298-302, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shetty, H. U.
Right arrow Articles by Schapiro, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shetty, H. U.
Right arrow Articles by Schapiro, M. B.

Clinical Chemistry, Vol 42, 298-302, Copyright © 1996 by American Association for Clinical Chemistry

Cerebrospinal fluid and plasma distribution of myo-inositol and other polyols in Alzheimer disease

HU Shetty, HW Holloway and MB Schapiro
Laboratory of Neurosciences, National Institute on Aging, National Institutes of Health, Bethesda, MD 20892-1582, USA.

Previous studies suggest the presence of increased concentrations of cerebral myo-inositol in Alzheimer disease (AD). To characterize this abnormality further, we quantified myo-inositol and several other polyols in cerebrospinal fluid (CSF) and plasma from 10 AD subjects and 10 healthy age-matched controls by using a gas chromatographic-mass spectrometric technique. The mean CSF concentration and CSF/plasma concentration ratio of myo-inositol in AD were not significantly different from those determined in control subjects. Also, concentration profiles of other polyols were not significantly altered in AD. CSF and plasma myo-inositol concentrations were correlated in control subjects but not in AD subjects. However, a significant correlation between CSF and plasma 1,5-anhydrosorbitol (a polyol internal control) concentrations observed in control subjects was retained in AD subjects.


The following articles in journals at HighWire Press have cited this article:


Home page
 Am. J. PsychiatryHome page
W. Huang, G. E. Alexander, E. M. Daly, H. U. Shetty, J. S. Krasuski, S. I. Rapoport, and M. B. Schapiro
High Brain myo-Inositol Levels in the Predementia Phase of Alzheimer’s Disease in Adults With Down’s Syndrome: A 1H MRS Study
Am J Psychiatry, December 1, 1999; 156(12): 1879 - 1886.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.